Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

NCT07220811 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Ig-E Mediated Food Allergy

Interventions

DRUG: RPT904
DRUG: RPT904
OTHER: Placebo
DRUG: RPT904
DRUG: RPT904
OTHER: Placebo

Sponsor

RAPT Therapeutics, Inc.